With the ambition to make its AGuIX® nanodrug a standard of care in the treatment of certain cancers by radiotherapy, NH TherAguix announces the launch of its initial public offering on the Euronext Growth market in Paris on 28 September 2021.
By 11 October 2021, the company expects to increase its capital by approximately €30 million to approximately €39.7 million. Its shareholders Bpifrance, Financière Arbevel, Supernova Invest and the Guerbet Group, an international expert in medical imaging, have committed to subscribing up to €9.85 million.
Founded in 2015 in Grenoble, NH TherAguix specialises in the development of innovative nanomedicines. AGuIX increases the effectiveness of radiotherapy on solid tumours, while preserving the surrounding healthy tissue. Its CEO and co-founder Géraldine Le Duc has announced that she is seeking €30 million to continue her phase I and II clinical trials. The aim is to be able to apply for a first registration of its nanodrug by 2025. She says that of the indications being tested, three are already being recruited and four have been given the green light by the health authorities.